Search Results

Showing results 71-81 of 84 for 'Cancer treatment'


  • hockey.png
  • shachar-idit_2-tn.jpg
    Target: Blood Cancers

    Read about Prof. Idit Shachar's search for an improved treatment for chronic lymphocytic leukemia and other blood cancers. She and her team discovered a blocking antibody that showed great promise in killing cancer cells in a clinical trial. Prof. Shachar also addresses the challenges of being a woman (and mom) in science. This is WeizmannViews Issue No. 45.

    /news-media/feature-stories/target-blood-cancers
  • What is Immunotherapy?
  • Ayelet-Erez.jpg
    Rare Genetic Defect May Lead to Cancer Drug

    The path to understanding what goes wrong in cancer could benefit from a detour through studies of rare childhood diseases. Dr. Ayelet Erez explains that cancer generally involves dozens – if not hundreds – of mutations, and sorting out the various functions and malfunctions of each may be nearly impossible. Rare childhood diseases, in contrast, generally involve mutations to a single gene.

    /news-media/news-releases/rare-genetic-defect-may-lead-to-cancer-drug
  • Screen Shot 2017-05-23 at 1.41.14 PM.png
  • Untitled-2-1[1]-Eshhar-1.jpg
    Breakthrough Israeli Cancer Professor on Prowl to Ease Other Ills

    Prof. Zelig Eshhar’s phones haven’t stopped ringing since the news broke two days ago that Israeli-founded Kite Pharma would be bought by US pharma company Gilead Sciences Inc. for a whopping $12 billion. Eshhar, a researcher at Israel’s Weizmann Institute of Science, developed the technology which is at the heart of Monday’s acquisition. He is also on Kite’s scientific advisory board, and was one of the first people to get a call from Kite CEO and founder, Israeli-American oncologist Arie Belldegrun, after the deal was signed.

    /news-media/in-the-news/breakthrough-israeli-cancer-professor-on-prowl-to-ease-other-ills
  • acwis_40538065321-Zelig-Esshar.jpg
  • acwis_38036303583-Straussman-1.jpg
    How Bacteria Hinder Chemotherapy

    To the list of reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study just published in Science, researchers describe their findings showing that certain bacteria can be found inside human pancreatic tumors. The findings further revealed that some of these bacteria contain an enzyme that inactivates a common drug used to treat various cancers, including pancreatic cancer. Working with mouse models of cancer, the scientists demonstrated how treatment with antibiotics on top of chemotherapy may be significantly superior to treatment with chemotherapy alone.

    /news-media/news-releases/how-bacteria-hinder-chemotherapy
  • shutterstock_309289829.jpg
  • c26_HA800[1].jpg
    EMA Approves Steba’s Prostate Cancer Drug

    The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended by a majority of 29-2 the approval for marketing of the Tookad drug for treatment of prostate cancer developed by Israeli company Steba Biotech. Tookad is a complex treatment, in which the patient takes a drug, but the drug is activated only in the area of the tumor, through the skin. The product, developed by Professor Avigdor Scherz and Dr. Yoram Salomon of the Weizmann Institute of Science, has already been approved for marketing and sale in Israel and Mexico.

    /news-media/in-the-news/ema-approves-steba-s-prostate-cancer-drug